Is It Too Late to Buy Eli Lilly Stock Now?
https://www.fool.com/investing/2024/03/02/is-it-too-late-to-buy-eli-lilly-stock-now/?source=iedfolrf0000001
Mar 02, 2024 - Eli Lilly stock is having a moment, but the company could easily continue soaring.
0
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
https://www.fool.com/investing/2024/03/17/3-unstoppable-stocks-you-can-buy-now-without-any/?source=iedfolrf0000001
Mar 17, 2024 - There's no need for delays in buying these great stocks.
0
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
https://www.fool.com/investing/2024/03/28/bull-market-buys-3-dividend-stocks-to-own-for-the/?source=iedfolrf0000001
Mar 28, 2024 - Invest in stability, dividends, and growth with these three accomplished real estate operators.
0
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
https://www.fool.com/investing/2024/03/28/stock-split-watch-are-these-2-top-growth-stocks/?source=iedfolrf0000001
Mar 28, 2024 - Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
0
The Next "Magnificent Seven"?
https://www.fool.com/investing/2024/04/10/the-next-magnificent-seven/?source=iedfolrf0000001
Apr 10, 2024 - Here is a look at the stocks that might comprise the next "Magnificent Seven."
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
https://www.zacks.com/stock/news/2193099/roche-rhhby-to-acquire-obesity-drug-maker-carmot-for-2-7b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193099
Dec 04, 2023 - Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
0
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
https://www.zacks.com/stock/news/2193345/is-it-a-good-idea-to-invest-in-ac-immune-aciu-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2193345
Dec 05, 2023 - Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
https://www.zacks.com/stock/news/2201371/should-ishares-msci-usa-min-vol-factor-etf-usmv-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2201371
Dec 22, 2023 - Style Box ETF report for USMV
0